Serum EV-MDM2 may be the first biomarker May 22, 2024 by Dr. Harsh J Shah – Pancreas, Liver, Gastro & Cancer Surgeon Leave a Comment Serum EV-MDM2 may be the first biomarker for retroperitoneal liposarcoma (RLS) recurrence. EV-MDM2 levels drop post-surgery but rise with recurrence. This can guide early detection and treatment decisions.
Leave a Reply